| Drug Type Fc fusion protein, Biosimilar | 
| Synonyms Etanercept biosimilar, Nanercept | 
| Target | 
| Action inhibitors | 
| Mechanism LTα inhibitors(Tumor necrosis factor β inhibitors), TNF-α inhibitors(Tumor necrosis factor α inhibitors) | 
| Therapeutic Areas | 
| Active Indication | 
| Inactive Indication- | 
| Originator Organization | 
| Active Organization | 
| Inactive Organization- | 
| License Organization- | 
| Drug Highest PhaseApproved | 
| First Approval Date Vietnam (01 Jan 2019),  | 
| Regulation- | 

| KEGG | Wiki | ATC | Drug Bank | 
|---|---|---|---|
| - | - | - | 
| Indication | Country/Location | Organization | Date | 
|---|---|---|---|
| Psoriasis | Vietnam  | 01 Jan 2019 | |
| Rheumatoid Arthritis | Vietnam  | 01 Jan 2019 | 
| Not Applicable | 2,030 | ETA-treated patients who switched to SB4 | vecgoltgcu(flromhrcoo) = gyoayptlyt ijcmxrmtuk (gdhccstlqi ) | - | 06 Nov 2017 | 






